Related references
Note: Only part of the references are listed.Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years
Brandon Essink et al.
CLINICAL INFECTIOUS DISEASES (2022)
Does the rise in seasonal respiratory viruses foreshadow the return of invasive pneumococcal disease this winter?
Zahin Amin-Chowdhury et al.
LANCET RESPIRATORY MEDICINE (2022)
PCV13 Vaccination of Adults against Pneumococcal Disease: What We Have Learned from the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA)
Christian Theilacker et al.
MICROORGANISMS (2022)
Incidence of acute lower respiratory tract disease hospitalisations, including pneumonia, among adults in Bristol, UK, 2019, estimated using both a prospective and retrospective methodology
Catherine Hyams et al.
BMJ OPEN (2022)
Streptococcus pneumoniae colonization associates with impaired adaptive immune responses against SARS-CoV-2
Elena Mitsi et al.
JOURNAL OF CLINICAL INVESTIGATION (2022)
Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Invasive Pneumococcal Disease and Risk of Pneumococcal Coinfection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Prospective National Cohort Study, England
Zahin Amin-Chowdhury et al.
CLINICAL INFECTIOUS DISEASES (2021)
NHS gets £5.9bn funding boost in autumn budget to tackle waiting lists in England
Elisabeth Mahase
BMJ-BRITISH MEDICAL JOURNAL (2021)
Winter pressure: RSV, flu, and covid-19 could push NHS to breaking point, report warns
Elisabeth Mahase
BMJ-BRITISH MEDICAL JOURNAL (2021)
Pneumococcal serotype trends, surveillance and risk factors in UK adult pneumonia, 2013-18
Harry Pick et al.
THORAX (2020)
Characteristics of Invasive Pneumococcal Disease Caused by Emerging Serotypes After the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in England: A Prospective Observational Cohort Study, 2014-2018
Zahin Amin-Chowdhury et al.
CLINICAL INFECTIOUS DISEASES (2020)
Cost-effectiveness of continuing pneumococcal conjugate vaccination at age 65 in the context of indirect effects from the childhood immunization program
Charles Stoecker et al.
VACCINE (2020)
Clinical and financial burden of hospitalised community-acquired pneumonia in patients with selected underlying comorbidities in England
James Campling et al.
BMJ OPEN RESPIRATORY RESEARCH (2020)
Pneumonia incidence trends in UK primary care from 2002 to 2017: population-based cohort study
Xiaohui Sun et al.
EPIDEMIOLOGY AND INFECTION (2019)
The impact of certain underlying comorbidities on the risk of developing hospitalised pneumonia in England
J. Campling et al.
PNEUMONIA (2019)
Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study
Shamez N. Ladhani et al.
LANCET INFECTIOUS DISEASES (2018)
Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine and Changes in Invasive Pneumococcal Disease Incidence from 2000 to 2017 in Those Aged 65 and Over in England andWales
Abdelmajid Djennad et al.
ECLINICALMEDICINE (2018)
Shortage of general practitioners in the NHS
Azeem Majeed
BMJ-BRITISH MEDICAL JOURNAL (2017)
Shortage of general practitioners in the NHS
Azeem Majeed
BMJ-BRITISH MEDICAL JOURNAL (2017)
Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea
Jung Yeon Heo et al.
PLOS ONE (2017)
Long-term mortality of hospitalized pneumonia in the EPIC-Norfolk cohort
P. K. Myint et al.
EPIDEMIOLOGY AND INFECTION (2016)
Serotype-specific differences in short- and longer-term mortality following invasive pneumococcal disease
G. J. Hughes et al.
EPIDEMIOLOGY AND INFECTION (2016)
Incremental Cost-Effectiveness of 13-valent Pneumococcal Conjugate Vaccine for Adults Age 50 Years and Older in the United States
Charles Stoecker et al.
JOURNAL OF GENERAL INTERNAL MEDICINE (2016)
NHS funding in England: money's too tight to mention
Jennifer Dixon et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
NHS funding in England: money's too tight to mention
Jennifer Dixon et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults
Neil French et al.
MALAWI MEDICAL JOURNAL (2016)
Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands
Marie-Josee J. Mangen et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults
M. J. M. Bonten et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Economic Evaluation of Immunisation Programme of 23-Valent Pneumococcal Polysaccharide Vaccine and the Inclusion of 13-Valent Pneumococcal Conjugate Vaccine in the List for Single-Dose Subsidy to the Elderly in Japan
Shu-ling Hoshi et al.
PLOS ONE (2015)
Resource use by patients hospitalized with community-acquired pneumonia in Europe: analysis of the REACH study
Helmut Ostermann et al.
BMC PULMONARY MEDICINE (2014)
Modeling of Cost Effectiveness of Pneumococcal Conjugate Vaccination Strategies in US Older Adults
Kenneth J. Smith et al.
AMERICAN JOURNAL OF PREVENTIVE MEDICINE (2013)
Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions
Bo-Hyun Cho et al.
VACCINE (2013)
Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy
Sara Boccalini et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2013)
Vaccines for preventing pneumococcal infection in adults
Sarah Moberley et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2013)
The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England
Albert Jan van Hoek et al.
JOURNAL OF INFECTION (2012)
Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales
Nick J. Andrews et al.
VACCINE (2012)
Potential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in Germany
Alexander Kuhlmann et al.
HEALTH ECONOMICS REVIEW (2012)
A Trial of a 7-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults.
Neil French et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Alternative strategies for adult pneumococcal polysaccharide vaccination: A cost-effectiveness analysis
Kenneth J. Smith et al.
VACCINE (2008)
Effect of pneumococcal vaccination in hospitalized adults with community-acquired pneumonia
Jennie Johnstone et al.
ARCHIVES OF INTERNAL MEDICINE (2007)
Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries
S. M. A. A. Evers et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2007)
A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection
KP Klugman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: Role of comorbid conditions and race
JE Sisk et al.
ANNALS OF INTERNAL MEDICINE (2003)
Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly
AM Fry et al.
VACCINE (2002)
Share Paper
